• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted)

  • Profile

Profile

Contact Information

Contact: Seqirus
Website: www.seqirus.com

Currently Enrolling Trials

    Show More

    General Information

    Audenz is an adjuvanted, cell-based influenza vaccine.

    Audenz is specifically indicated to help protect individuals six months of age and older against influenza A (H5N1) in the event of a pandemic.

    Audenz is supplied as an injectable emulsion for intramuscular use. Administer two doses of Audenz (0.5 mL each), 21 days apart.

    Mechanism of Action

    Audenz combines Seqirus’ MF59 adjuvant and cell-based antigen manufacturing. The MF59 adjuvant is believed to enhance an immune response from the body by inducing antibodies against virus strains that have mutated. The adjuvant reduces the amount of antigen required to produce an immune response, increasing the number of doses of the vaccine developed, so that a large number of people can be protected as quickly as possible.

    The vaccine is designed to be rapidly deployed to help protect the U.S. population and can be stockpiled for first responders in the event of pandemic.

    Side Effects

    Adverse effects associated with the use of Audenz may include, but are not limited to, the following:

    • In adults 18 through 64 years of age, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were injection site pain, fatigue headache, malaise, myalgia, arthralgia and nausea.
    • In adults 65 years of age and older, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were injection site pain, fatigue, malaise, headache and arthralgia. 
    • In infants and children, 6 months through 5 years of age, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were tenderness, irritability, sleepiness, change in eating habits and fever.
    • In children 6 through 17 years of age, the most common (≥ 10%) solicited local and systemic reactions reported in clinical trials were injection site pain, myalgia, fatigue, malaise, headache, loss of appetite, nausea and arthralgia.

    Clinical Trial Results

    Seqirus presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore in August of 2019. The data are from clinical studies demonstrating the ability of a MF59 adjuvanted influenza vaccine to increase immune responses when used in both seasonal and pandemic influenza vaccines, across pediatric and adult populations. In the pediatric Phase II study (V89_11), a total of 322 subjects aged 6 months through 17 years received full doses of a MF59 adjuvanted, cell-derived influenza A (H5N1) vaccine (aH5N1c) three weeks apart. In two separate but similar adult and elderly Phase II studies (V89_13; V89_04), a total of 975 subjects aged 18 to 64 years of age and 1,388 subjects 65 years of age and older were equally randomized to received two full or half doses of a MF59 adjuvanted, cell-derived influenza A (H5N1) vaccine (aH5N1c) three weeks apart. A full dose was 7.5 μg HA of H5N1 with 0.25 mL MF59 for a total injection volume of 0.5 mL, and a half-dose was 3.75 μg HA of H5N1 with 0.125 mL MF59 for a total injection volume of 0.25 mL.

    Antibody responses against five pre-determined H5N1 clades were measured by hemagglutination inhibition (HI) and microneutralization (MN) assays in pre-defined exploratory analyses. Adult and elderly subjects that received the full dose demonstrated increased immunogenicity against heterologous A (H5N1) strains from five different clades. Pediatric subjects that received the full dose demonstrated increased immunogenicity against heterologous A (H5N1) strains.

    Approval Date: 2020-02-01
    Company Name: Seqirus
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing